Sutro Biopharma Inc.
Sutro Biopharma Inc. is listed today as Sutro Biopharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2018 | $85 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Sutro Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2018).
SEC Form D · Aug 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2018
That is all the official record says: Sutro Biopharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Sutro Biopharma Inc. are on record.
Investors#
19 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Partners Management VIII, LLC | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Alta Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Celgene Corp /de/ | Company | not stated | not stated | Held Series C-2, D, D-2 and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Edward C. Albini | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2018) | SEC Form 3 |
| Ilsf III, LLC | Other | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| International Life Sciences Fund III Co-Investment, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| International Life Sciences Fund III (GP), L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| International Life Sciences Fund III (LP1), L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| International Life Sciences Fund III Strategic Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Merck & Co., Inc. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Merck Sharp & Dohme Corp. | Company | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Skyline Venture Management V, LLC | Venture capital | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Skyline Venture Partners V LP | Venture capital | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| SV Life Sciences Fund V (GP), LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| SV Life Sciences Fund V LP | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| SV Life Sciences Fund V Strategic Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Svlsf V, LLC | Other | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Trevor Hallam | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2018) | SEC Form 3 |
| William J. Newell | Person | not stated | not stated | Held Series C and D preferred stock, director (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 15 investors.
Largest shareholders today
Institutions holding Sutro Biopharma, Inc. shares, as of Sep 30, 2026.
- BVF Inc/il$20 M7.54%
- BlackRock, Inc.$19 M7.10%
- Affinity Asset Advisors, LLC$19 M6.94%
- Samsara Biocapital, LLC$17 M6.40%
- Perceptive Advisors LLC$16 M5.85%
- Kynam Capital Management, LP$14 M5.26%
- Orbimed Advisors LLC$12 M4.48%
- Vanguard Capital Management LLC$11 M4.08%
- Acadian Asset Management LLC$9 M3.36%
- Velan Capital Investment Management LP$8 M3.07%
- Goldman Sachs Group Inc$8 M2.99%
- T. Rowe Price Investment Management, Inc.$7 M2.48%
- Qube Research & Technologies Ltd$6 M2.28%
- Geode Capital Management, LLC$6 M2.20%
- Two Sigma Investments, LP$6 M2.16%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| William J. Newell | Executive officer | Aug 2018 |
| Armen Bryan Shanafelt | Director | Aug 2018 |
| Daniel Bryan Petree | Director | Aug 2018 |
| Daniel J. Janney | Director | Aug 2018 |
| John G. Freund | Director | Aug 2018 |
| Joseph Bryan Lobacki | Director | Aug 2018 |
| Michael Bryan Dybbs | Director | Aug 2018 |
| Michael Bryan Ross | Director | Aug 2018 |
| Virgil Bryan Lawlis | Director | Aug 2018 |
| William J. Newell | Director | Aug 2018 |
| Armen G. Shanafelt | Director | Jun 2018 |
| Bryan G. Lawlis | Director | Jun 2018 |
| Joseph G. Lobacki | Director | Jun 2018 |
| Michael G. Ross | Director | Jun 2018 |
About
Company.
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.